Schottky heterojunction CeO 2 @MXene nanosheets with synergistic type I and type II PDT for anti-osteosarcoma

Photodynamic therapy (PDT) has shown great potential for tumor treatment as the method is noninvasive, highly selective, and causes minimal side effects. However, conventional type II PDT, which relies on O , presents poor therapeutic efficacy for hypoxic tumors due to its reliance on oxygen. Here,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of materials chemistry. B, Materials for biology and medicine Materials for biology and medicine, 2024-02, Vol.12 (7), p.1816-1825
Main Authors: Zheng, Bingxin, Zhang, Ranran, Kuang, Fei, Hui, Tiankun, Fu, Chenchen, Zhang, Li, Zhou, Chuanli, Qiu, Meng, Yue, Bin
Format: Article
Language:English
Subjects:
Bone Neoplasms
Humans
Hydrogen Peroxide
Hypoxia
Nitrites
Osteosarcoma
Oxygen
Transition Elements
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Photodynamic therapy (PDT) has shown great potential for tumor treatment as the method is noninvasive, highly selective, and causes minimal side effects. However, conventional type II PDT, which relies on O , presents poor therapeutic efficacy for hypoxic tumors due to its reliance on oxygen. Here, CeO /Ti C -MXene (CeO @MXene) hybrids were successfully designed by growing CeO using Ti C -MXene (MXene) nanosheets. CeO @MXene serves as a reduction-oxidation (REDOX) center due to the presence of Ce in the lattice of CeO nanoparticles. This REDOX center reacts with H O to generate oxygen and weakens the hypoxic tumor cell environment, achieving type II PDT. At the same time, many other ROS (such as ⋅O and ⋅OH) can be produced a type I photodynamic mechanism (electron transfer process). The CeO @MXene heterojunction performs nanoenzymatic functions for synergistic type I and type II PDT, which improves cancer treatment.
ISSN:2050-750X
2050-7518
DOI:10.1039/d3tb02835f